IV iron may beat pills for anemia in late pregnancy

NCT ID NCT04253626

Completed Disease control Sponsor: Stanford University Source: ClinicalTrials.gov ↗

First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time

Summary

This study tests whether a single intravenous dose of ferumoxytol raises hemoglobin more effectively than daily oral ferrous sulfate in pregnant women with iron deficiency anemia. Participants are between 24 and 34 weeks pregnant with a single baby. The trial measures hemoglobin changes, side effects, and whether fewer women need blood transfusions after delivery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ferumoxytol (intravenous) and ferrous sulfate (oral)
What this could lead to: If IV iron works better, it could offer a faster, more effective treatment for anemia in late pregnancy, reducing the need for blood transfusions.
What could go wrong: This is a single-center trial with 83 participants, so results may not apply broadly. IV iron carries a small risk of allergic reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANEMIA, IRON DEFICIENCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

iron deficiency anemia pregnancy disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANEMIA, IRON DEFICIENCY PREGNANCY RELATED

Contacts and locations

Locations

Stanford University School of Medicine/Lucile Packard Childrens Hospital

Stanford, California, 94305, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.